Analyst Rating Update on Endologix (ELGX)

Endologix (ELGX) : 7 brokerage houses believe that Endologix (ELGX) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 8 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.13.

Endologix (ELGX) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $17 and the lowest price target forecast is $15. The average forecast of all the analysts is $15.93 and the expected standard deviation is $0.61.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Brokerage Firm, BMO Capital, upgrades their rating on the shares of Endologix (NASDAQ:ELGX). BMO Capital has a Outperform rating on the shares. Previously, the analysts had a Market Perform rating on the shares. As per the latest research report, the brokerage house raises the price target to $16 per share from a prior target of $11.5. The rating by the firm was issued on July 7, 2016.


Endologix (NASDAQ:ELGX): The stock opened at $12.00 on Wednesday but the bulls could not build on the opening and the stock topped out at $12.48 for the day. The stock traded down to $11.78 during the day, due to lack of any buying support eventually closed down at $11.99 with a loss of -12.84% for the day. The stock had closed at $13.75 on the previous day. The total traded volume was 7,997,594 shares.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.